N/A
N=20
Intra-articular Injection in Arthroscopic Management of Temporomandibular Diseases
Temporomandibular Joint Disorders
Bottom Line
View on ClinicalTrials.gov: NCT04936945 ↗Enrolled (actual)
20
Serious AEs
0.0%
Results posted
Sep 2024
Primary outcome: Primary: Maximum Interincisal Opening (MIO) Measurements — 23.1; 27.9; 33.8; 35.6 Millimeter
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Temporomandibular joint arthroscopy plus intra-articular injection (Procedure)
- Age
- Pediatric, Adult, Older Adult · 5+ yrs
- Sex
- All
- Sponsor
- Sohag University
- Primary completion
- May 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Maximum Interincisal Opening (MIO) Measurements |
23.1; 27.9; 33.8; 35.6; 36; 36.7 | — |
| PRIMARY Pain Intensity Measurements |
49; 49; 28; 30; 21; 25 | — |
Summary
The aim of this study is to evaluate the efficacy of intra-articular injection of platelet rich plasma versus hyaluronic acid following diagnostic arthroscopy in the management of patients suffering from degenerative temporomandibular joint (TMJ).
This is a prospective randomized study of 20 patients with TMJ degenerative joint diseases Wilkes IV, V.
Patients will be divided into two groups; Group A: will be treated with operative arthroscopy plus intra-articular platelet rich plasma.
Group B: will be treated with operative arthroscopy plus intra-articular hyaluronic acid.
Eligibility Criteria
Inclusion Criteria
- - All patients with reduced mouth opening and/or painful maximum mouth opening.
- Joint pain.
- Patients with radiological evidence of degenerative joint disease.
- Patients with unsuccessful medical conservative treatment for at least two months.
- Unilateral or bilateral temporomandibular joint involvement.
- Wilkes stages IV and V
Exclusion Criteria
- - Patients with bony ankylosis .
- Patients with advanced resorption of the glenoid fossa.
- Patients with infection or tumors around joint area
- Patients unfit for intervention medically.
- Patients who refused to share in the study
Data sourced from ClinicalTrials.gov (NCT04936945). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.